तुम्ही WORLD360 ची मराठी आवृत्ती वाचत आहात, जी सध्या तयार होत आहे. मेनू आणि शीर्षके मराठीत आहेत; भाषांतर तयार होईपर्यंत बातम्या इंग्रजीत दिसतील.

Earnings

RPG LS does not see material impact from the trade margin caps, says MD

RPG Life Sciences says the new 30% trade margin caps on cancer drugs will not materially affect its sales or profit margins.

◆2 स्वतंत्र स्रोत◆4 स्रोत नोंदी◆heat 0.32◆अपडेट: now

Outlets are counted by registrable domain, so a broadcaster’s station subdomains count once. 2 of the 4 items repeat an outlet already counted.

इंजिनचे आकलन14.7% overlap with its sources

RPG Life Sciences says the new 30% trade margin caps on cancer drugs will not materially affect its sales or profit margins.

Quarterly financial results

RPG Life Sciences reported revenue of ₹211.6 crore for the quarter ended September 30, 2026, a 16.5% increase and the second consecutive quarter above ₹200 crore.

Net profit fell 37% to ₹23.29 crore, which the company attributed to one‑time acquisition costs, while newly acquired sites added only ₹0.5 crore in the quarter and are expected to contribute fully from the next quarter.

Trade margin caps effect

The government imposed a 30% margin cap on 137 non‑scheduled cancer drugs, causing price drops for RPG LS products such as Bevacizumab (from ₹69,852.12 to ₹13,512) and Palbociclib (from ₹40,421.33 to ₹2,720).

Managing Director Ashok Nair said the caps primarily affect hospital‑level pricing, while the company's own selling prices remain largely unchanged, so it does not anticipate material revenue or margin dilution.

Strategic expansion moves

In October, RPG LS launched semaglutide for diabetes and obesity, expanding its specialty portfolio.

The firm also highlighted the creation of RPG Active Pharma and recent acquisitions of Actis and Raghava, emphasizing integration and value creation as part of its active pharmaceutical ingredient strategy.

Coverage

2 independent outlets filed 4 reports over 27 hours. Coverage is still building.

2outlets
4filings
27hspan
risingtrend
What could happen next
No outcome sealed yet.the engine has not sealed a forecast on this story yet. The forecast is always written to the ledger before any article about it, never the other way round.
पुरावे4 items
Dixon, Syrma clock revenue jump while chip costs rose

Both contract electronics manufacturers beat the Street in September quarter, with higher revenues.

EKA’s $1 billion bus book, ₹1,000 crore capex fuel push into trucks, six-seaters

Sudhir Mehta targets ₹2,800 crore in combined FY27 revenue as EKA Mobility expands manufacturing, electric freight and rural mobility operations

RPG LS does not see material impact from the trade margin caps, says MD

RPG LS revenue from operations grew 16.5 percent to ₹211.6 crore, for the quarter ended September 30, 2026

Over 100 of the 600-plus medicines listed by NPPA do not show a drop in prices

Public health advocates call for cost-based pricing as trade margin caps leave costly cancer drugs untouched

Sources are evidence, not content. Each keeps its own name, its own link and an extract capped at 400 characters; none of it is rewritten into the copy above.

व्यवसाय मध्ये आणखी
1/8All →